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Abstract
Tamoxifen has been used for many years to target estrogen receptor signalling in breast cancer cells. Tamoxifen is also an
agonist of the G protein-coupled estrogen receptor (GPER), a GPCR ubiquitously expressed in tissues that mediates the
acute response to estrogens. Here we report that tamoxifen promotes mechanical quiescence in hepatic stellate cells (HSCs),
stromal fibroblast-like cells whose activation triggers and perpetuates liver fibrosis in hepatocellular carcinomas. This
mechanical deactivation is mediated by the GPER/RhoA/myosin axis and induces YAP deactivation. We report that
tamoxifen decreases the levels of hypoxia-inducible factor-1 alpha (HIF-1α) and the synthesis of extracellular matrix
proteins through a mechanical mechanism that involves actomyosin-dependent contractility and mechanosensing of tissue
stiffness. Our results implicate GPER-mediated estrogen signalling in the mechanosensory-driven activation of HSCs and
put forward estrogenic signalling as an option for mechanical reprogramming of myofibroblast-like cells in the tumour
microenvironment. Tamoxifen, with half a century of safe clinical use, might lead this strategy of drug repositioning.
Introduction
The G protein-coupled estrogen receptor (GPER) is a seven
transmembrane G protein-coupled receptor (GPCR) that
mediates the acute response to extracellular estrogens [1, 2].
Agonists for GPER include endogenous estrogens such as
17β-estradiol, as well as synthetic compounds, such as
tamoxifen and fulvestrant. Tamoxifen is a GPER agonist that
has been used in clinics for more than 50 years as hormonal
therapy for breast cancer based on the classical genomic
estrogen receptor (ER) signalling pathway, unrelated to
GPER. Interestingly, tamoxifen has also been used in women
at risk of developing breast cancer and has been observed to
reduce mammographic density and fibrosis [3, 4]. Due to its
established pharmacology and non-toxicity, tamoxifen is well
positioned to lead our efforts in exploring novel modes of
action for this drug and investigating the possible clinical
benefits of GPER-mediated estrogen signalling.
Hepatocellular carcinoma (HCC) is the most common
form of primary liver cancer and, regardless of aetiology,
occurs predominantly in patients with cirrhosis, which is
characterised by excessive extracellular matrix (ECM)
deposition that presents the ideal environment for promot-
ing tumour formation. In this environment, hepatocyte
necrosis, inflammation, oxidative stress and hypoxia are
responsible for genetic alterations and deregulation of sig-
nalling pathways that promote HCC development [5–7]. It
is also known that inflammation in the stroma in HCC can
be modulated by estrogens [8].
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Hepatic stellate cells (HSCs) are stroma resident
mesenchymal myofibroblast-like cells [9] which initiate and
modulate liver fibrosis by regulating the chemical [10] and
mechanical [11] composition of the ECM. HSCs, like other
myofibroblast-like cells [12], are highly responsive to
mechanical cues, requiring a stiff microenvironment to
become activated and therefore initiate and perpetuate
fibrosis. They achieve this by (i) activating their contractile
apparatus to apply endogenous forces to the ECM, and (ii)
mechanosensing the rigidity from their surroundings [13,
14]. Both processes, cell contractility and mechanosensing,
rely on activation of the small GTPase RhoA [15, 16].
RhoA is essential in maintaining the activated phenotype of
HSCs, by ensuring cell contractility through regulation of
ROCK and other modulators of actomyosin [17].
Here we report that tamoxifen induces the mechanical
deactivation of HSCs via a previously unidentified
mechanism that involves the GPER/RhoA/myosin axis.
This inhibits activation of YAP (Yes-associated protein)
and durotaxis in HSCs. We also show that cell contractility
and ECM rigidity regulate the levels of hypoxia-inducible
factor 1 alpha (HIF-1α) and lysyl oxidase (LOX) in HSCs,
and that tamoxifen suppresses force-mediated regulation of
both HIF-1α and LOX. HIF-1α is fundamental for cell
survival in hypoxic conditions [18], as the LOX family
regulates collagen crosslinking and ECM architecture and is
therefore required for hypoxia-induced metastasis.
Results
Tamoxifen treatment reduces myosin activation in
HSCs via GPER/RhoA signalling
Actomyosin contractility is a key characteristic of activated
HSCs, allowing mechanotransduction and force generation.
This behaviour is adaptive in wound healing but promotes
fibrosis in HCC [11]. Regulation of actomyosin contractility
is achieved through phosphorylation of the regulatory pro-
tein myosin light chain 2 (MLC-2). Tamoxifen is a 17β-
estradiol mimetic that activates GPER, and has been well
characterised in its ability to selectively modulate estrogen
receptors [19]. We used immunofluorescence staining to
confirm the presence of GPER and the canonical estrogen
receptors alpha and beta (ER-α and ER-β) in HSCs (Sup-
plementary Fig S1). We also confirmed the levels of
expression of GPER in HSCs using immunoblotting/
immunofluorescence and GPER knockdown/over-
expression (Supplementary Fig S2-S4). To assess acto-
myosin contractility, we determined the levels of active
phosphorylated MLC-2 (pMLC-2), as well as the total
MLC-2, in response to 10-day treatment with tamoxifen.
We also included conditions with antagonists against ER
and GPER to explore which receptor tamoxifen acted
through. We used the selective ER antagonist (ICI182780)
[20] and the specific GPER antagonist G15 [21]. For this
experiment and the subsequent ones, ICI182780 and G15
were used simultaneously with tamoxifen treatment.
Across all four conditions (control, tamoxifen, tamoxifen
+ ER antagonist, tamoxifen+GPER antagonist), the stain-
ing intensity for MLC-2 remained constant, indicating that
protein expression was unchanged following treatment (Fig.
1a, b). Levels of pMLC-2 were significantly reduced in the
tamoxifen and tamoxifen+ ER antagonist conditions com-
pared to control, indicating that tamoxifen greatly reduces
MLC-2 phosphorylation, but does not act through the
nuclear estrogen receptors. Conversely, tamoxifen+GPER
antagonist showed pMLC-2 staining intensity comparable to
the control condition, suggesting that tamoxifen achieves
inhibition of MLC-2 activation through GPER (Fig. 1a, b).
To further confirm the specific role of GPER, we per-
formed experiments with siRNA to knockdown GPER
expression, in combination with tamoxifen or the estrogen
17β-estradiol (E2). Treatment was performed for 72 h since
GPER knockdown with siRNA is only stable for this
amount of time. We observed that 72-h treatment of HSCs
with either tamoxifen or E2 led to a decrease in pMLC-2
without affecting MLC-2 abundance, similar to 10-day
tamoxifen treatment. Knockdown of GPER with siRNA
GPER showed abundance of pMLC-2 comparable to the
control condition, even in the presence of tamoxifen or E2
(Supplementary Fig S5). This demonstrates that estrogenic
signalling, instigated by either tamoxifen or E2, acts
through GPER to reduce MLC-2 phosphorylation. Like-
wise, we assessed the effect of tamoxifen on the activation
of MLC-2 after 24-h treatment and observed that while the
total levels of MLC-2 were kept constant, pMLC-2 were
significantly decreased in the tamoxifen group and this
effect was mediated by GPER (Supplementary Fig S6).
RhoA lies upstream of MLC-2 and controls MLC-2
activation [22]. We quantified the levels of total RhoA and
active RhoA levels in HSCs under tamoxifen treatment.
Both control and 10 day tamoxifen treated conditions
showed similar levels of total RhoA. Control cells exhibited
active RhoA levels of around 50% of total RhoA, sig-
nificantly higher than in the tamoxifen treated cells where
active RhoA levels were around 20% (Fig. 1c). Taken
together, these data suggest that tamoxifen reduces myosin
activation via the GPER/RhoA/MLC-2 axis.
GPER activation in HSCs impairs force generation
and increases cell compliance
To further assess the effects of tamoxifen on cell con-
tractility, we used elastic pillars as a form of traction force
microscopy. This technique assesses the individual force
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applied to fibronectin-coated polydimethylsiloxane pillars
during cell spreading. Using the deflection of each pillar in
contact with the cell and the known Young’s modulus of
each pillar in the array, quantitative analysis of force gen-
eration was achieved. We report the value of mean max-
imum force, calculated from the mean value of the
maximum force experienced by each pillar with cellular
contact during the time of analysis. Control HSCs generated
a mean maximum force of around 3.2 nN, and following
10-day tamoxifen treatment, this mean maximum force was
significantly reduced to around 1.2 nN. When a GPER
antagonist was present alongside tamoxifen, the mean
maximum force returned to a value comparable to control
and significantly higher than tamoxifen alone (Fig. 2a, b).
Both 72-h tamoxifen treatment and E2 treatment also sig-
nificantly reduced traction forces in HSCs, but force gen-
eration was rescued in the presence of siRNA against
GPER. Additionally, G1, a specifically designed GPER
agonist [23], reduced traction forces, but did not with GPER
knockdown (Supplementary Fig S7). These results indicate
that GPER regulates cell traction forces, with tamoxifen, E2
and G1 all acting as GPER agonists.
The ability of cells to generate force is also dependent on
their rheological properties such as cell stiffness [24, 25].
Drugs that disrupt the cytoskeleton are known to inhibit the
activated phenotype of HSCs [26] and these types of drugs
have also been shown to decrease cell stiffness [27]. We
used atomic force microscopy (AFM) indentation of HSCs
seeded on fibronectin-coated fluorodishes to determine cell
elasticity. By indenting the cells at points between the
nucleus and the cell edge, we ensured that our analysis
would accurately assess the contribution of the cytoskeleton
to cell elasticity, and would be unaffected by the nucleus or
the underlying substrate.
We observed that control HSCs had a Young’s modulus
around 4.1 kPa, and this was significantly reduced to around
1.7 kPa with 10-day tamoxifen treatment. However, with a
GPER antagonist, tamoxifen was unable to reduce the
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Fig. 1 GPER activation in HSCs suppresses activation of MLC-2. a
Representative images for immunofluorescence staining of HSCs,
scale bar 50 µm. b Quantification of immunofluorescence staining for
panel a. MFI mean fluorescence intensity, 12 fields of views with
approximately 20 cells per field per condition. c Quantification of total
and active RhoA, expressed as percentage of the total RhoA in the
control condition, three biological samples analysed in three different
experiments. All histogram bars represent mean ± sem, **P < 0.01,
***P < 0.001. Anova and Tukey’s test for b and t-test for (c). Three
experimental replicates in all panels
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Young’s modulus, and cells had an average Young’s
modulus similar to the control condition (Fig. 2c). 72-h
treatment with either tamoxifen, E2 or G1 reduced cell
stiffness, but not in the presence of siRNA against GPER
(Supplementary Fig S7).
GPER activation reduces HSC mechanosensing and
YAP activation
We used magnetic tweezers microrheology to assess the
ability of HSCs to respond to external mechanical forces, as
would be experienced surrounded by a rigid stroma.
Fibronectin-coated magnetic beads were attached to cells,
and 12 consecutive pulses of equal force were applied with
magnetic tweezers. Cells that displayed mechanosensitivity
showed a reduction in bead displacement as the cytoskele-
ton reinforced following force application (Fig. 3a).
We observed that control HSCs showed mechan-
osensitivity, significantly reducing the displacement of the
bead on the 12th pulse to 71% of the displacement
measured on the 1st pulse. With 10 day tamoxifen treat-
ment, the 12th pulse had 85% of the displacement measured
on the 1st pulse, a value not significantly different from its
first pulse displacement, indicating a reduction in mechan-
otransduction. Using the GPER antagonist G15, mechan-
otransduction was restored to control levels, with the 12th
pulse at 68% compared to the 1st pulse (Fig. 3b).
The transcriptional regulator YAP is a key cellular
mechanotransducer, converting external mechanical signals
into changes in gene expression through its translocation to
the nucleus [28]. YAP has further been shown to be
essential in the mechanosensitive phenomenon of durotaxis
in HSCs [29]. We stained control and 10-day tamoxifen-
treated HSCs for YAP and assessed the intensity of staining
in both the nucleus and cytoplasm. The ratio between these
intensity values represents the level of YAP translocation to
the nucleus and therefore activation. Control HSCs showed
increased YAP nuclear localisation compared to 10-day
tamoxifen-treated HSCs, suggesting that tamoxifen reduces
levels of YAP mediated mechanotransduction (Fig. 3c, d).
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Fig. 2 Tamoxifen treatment impairs traction forces and increases cell
compliance in HSCs. a Heat maps representing forces applied by
HSCs on top of pillar arrays, scale bar 20 µm. b Quantification of
average forces applied by HSCs on pillars. n= 39 cells (control), 34
cells (tam) and 30 cells (tam and GPER antagonist). c Quantification of
cell compliance with atomic force microscopy. Cantilevers used had a
15 µm polystyrene bead attached. n= 60 cells (control), 42 cells (tam)
and 90 cells (tam and GPER antagonist). Mann–Whitney test for
significance, ***P < 0.001. All histogram bars represent mean ± sem,
**P < 0.01,***P < 0.001. Three experimental replicates in all panels
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Seventy-two-hour treatment of HSCs with either tamoxifen
or E2 also led to decreased YAP nuclear localisation, with
GPER knockdown rescuing localisation to that of control
HSCs (Supplementary Fig S8), indicating the specific role
of GPER in estrogen-mediated YAP deactivation. The
expression of the downstream YAP target genes CTGF and
ANKRD1 were reduced in 10 day tamoxifen treated HSCs,
in concurrence with the immunofluorescence data (Fig. 3e).
We then performed correlation analysis for the expression
profiles of the genes GPER, YAP and CTGF using the
TCGA (Cancer Genome Atlas) database, and found that
GPER expression in HCC patients negatively correlates
with the expression of YAP and CTGF (Fig. 3f).
Tamoxifen treatment induces HSC deactivation
Force generation and mechanotransduction are the two
pillars required for maintenance of the activated phenotype
of HSCs, similar to other myofibroblast-like cells [13, 30].
Since we observed tamoxifen to inhibit these mechanical
properties, we assessed whether tamoxifen could promote
HSC deactivation. We used immunofluorescence and qPCR
to assess levels of α-SMA and vimentin, both markers of the
activated phenotype. We observed a significant decrease in
both α-SMA and vimentin with tamoxifen treatment at both
the protein (Supplementary Fig S9) and mRNA (Supple-
mentary Fig S10) levels.
With GPER knocked down with siRNA for 72 h, we
observed no effect of tamoxifen in reducing the levels of
both markers of quiescence in HSCs (α-SMA and
vimentin), though 72 h treatment by tamoxifen did
decrease these levels. Likewise, treating HSCs with 17 β-
estradiol also downregulated the expression of α-SMA
and vimentin to levels comparable to those observed in
the tamoxifen group (Supplementary Fig S9). These
results support the notion that tamoxifen promotes
mechanical deactivation in HSCs through GPER/RhoA
signalling.
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Fig. 3 Tamoxifen treatment
suppresses mechanosensing and
YAP activation in HSCs.
a Representative trace that
shows the decrease in the
amplitude of oscillation of
a bead attached to a cell that can
sense external mechanical
stimuli (mechanosensing).
b Histogram shows relative bead
displacement for the first and
last pulse, n= 25 cells (control),
20 cells (tam) and 21 cells (tam
and GPER antagonist).
c Representative images for
immunofluorescence staining of
HSCs, scale bar 20 µm. The
white arrow indicates YAP
nuclear localization, whereas the
yellow arrow shows reduced
nuclear YAP localization.
d Quantification of YAP
nuclear/cytoplasmic ratio, 16
control cells and 16 tamoxifen
cells. e qPCR levels of YAP
downstream genes CTGF and
ANKRD1, normalized to
RPLP0 and relative to control,
three biological samples
analysed in three different
experiments. f Correlation
GPER/YAP/CTGF expressions
from TCGA database. Data from
492 patients. t-test, *P < 0.05,
**P < 0.01,***P < 0.001. Three
experimental replicates in all
cases
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Tamoxifen treatment suppresses ECM protein
production
A key role of activated HSCs in promoting further fibrosis
and disease development is their ability to produce high
levels of ECM proteins for secretion into their micro-
environment. Collagen-I and fibronectin are abundant pro-
teins within the ECM, playing critical roles in the
organisation and structural integrity of the environment, and
when overexpressed, can contribute to a pro-tumour
microenvironment [31]. We used immunofluorescence to
determine both the intracellular expression, and the extra-
cellular secretion, of both collagen-I and fibronectin. We
observed that 10-day tamoxifen treatment significantly
reduced the intracellular and extracellular levels of both
collagen-I (Fig. 4a, b, e) and fibronectin (Fig. 4c, d, f). 72-h
tamoxifen treatment also reduced intracellular collagen-I
and fibronectin levels, but could be rescued with GPER
knockdown. E2 treatment for 72-h also showed the same
trend (Supplementary Figure S11).
Due to the highly contractile phenotype of activated
HSCs, and their role in ECM protein production, we
assessed how enhancing contractile ability influenced
collagen-I and fibronectin expression. We transfected con-
trol HSCs with constitutively active myosin-2 (pMLC-2) to
increase cell contractility, and we observed significant
increases in expression of both collagen-I and fibronectin
(Fig. 4g), suggesting a mechanical basis to transcriptional
regulation of both ECM proteins by HSCs.
We also assessed how changes in matrix rigidity,
achieved through fabrication of different rigidity poly-
acrylamide (PAA) gels for cell culture, could change the
production of collagen-I and fibronectin. A 1 kPa gel, which
approximates the rigidity of healthy liver [32], was used as a
soft substrate and we observed that increasing this rigidity
to 25 kPa gave significant increases in collagen-I and
fibronectin mRNAs. We further observed that 10-day
tamoxifen treated HSCs on 25 kPa gels showed mRNA
levels of collagen-I and fibronectin comparable to the 1 kPa
condition, i.e. significantly lower than the 25 kPa condition
(Fig. 4h). This indicates that tamoxifen inhibits the
mechanical signalling pathway that connects external
rigidity and increased ECM deposition. Collectively these
results show that increased contractility and ECM stiffness
trigger a transcriptional increase in both collagen-I and
fibronectin in HSCs, and that tamoxifen inhibits this force-
mediated activation.
Tamoxifen treatment mechanically inhibits the HIF-
1α/LOX and HIF-1α/LOX-L2 axes
Liver fibrosis in HCC, along with excess consumption of
oxygen by hepatocytes, leads to tissue hypoxia, and the
survival of cells becomes dependent on expression of HIF-
1α [33]. Hypoxia, through HIF-1α, can regulate expression
of ECM protein genes, such as fibronectin [34] and
collagen-I [35]. HIF-1α has many other downstream targets,
including members of the lysyl oxidase (LOX) family.
Lysyl oxidases are copper-dependent enzymes that have
fundamental roles in ECM organization in cancer. For
instance, LOX is essential in hypoxia driven metastasis [36]
and LOX-L2 is involved in ECM remodelling in fibrosis
[37].
Mechanical induction of HIF-1α has also been observed
in endothelial cells exposed to low shear stress [38], and in
the myocardium in response to mechanical stress [39].
While hypoxia is the most common method of HIF-1α
activation, upregulation of HIF-1α expression has also been
seen in the presence of oxygen, with GPCRs on the cell
surface responding to microenvironmental cues [40].
We observed that levels of HIF-1α are reduced in HSCs
following 10-day tamoxifen treatment (Fig. 5a, b). Fur-
thermore, levels of LOX and LOX-L2 are also reduced with
tamoxifen (Fig. 5c–f), suggesting that the ability of HSCs to
cross-link collagen fibres in the ECM may be affected by
tamoxifen treatment. Similarly, 72-h treatment by tamoxifen
or E2 reduced levels of HIF-1α, LOX and LOX-L2, but no
reduction was seen with GPER knockdown (Supplementary
Figure S12).
Notably, we observed that the levels of HIF-1α, LOX
and LOX-L2 are responsive to mechanical cues indepen-
dent of tamoxifen-mediated signalling. The mRNA
expression of these proteins is increased following trans-
fection of HSCs with active myosin-2 (Fig. 5g). Similarly,
the culturing of HSCs on polyacrylamide gels of differing
rigidities also affected mRNA production. Compared to a 1
kPa substrate, HSCs cultured on a 25 kPa substrate showed
a significantly increased expression of HIF-1α, LOX and
LOX-L2 (Fig. 5h). This suggests that mechanotransduction
alone can drive processes that promote survival under
hypoxic conditions.
When tamoxifen was added to HSCs cultured on the stiff
25 kPa substrate for 10 days, levels of HIF-1α, LOX and
LOX-L2 were reduced, becoming equivalent to the levels of
these species on the soft 1 kPa substrate. To gain mechanistic
insight into tamoxifen-induced downregulation of LOX,
LOX-L2 and fibronectin, we used HIF-1α siRNA to knock-
down HIF-1α expression. We observed that the mRNA levels
of LOX, LOX-L2 and fibronectin, when treated with HIF-1α
siRNA, were equivalent to the mRNA levels seen with
tamoxifen treatment (Fig. 5i and Supplementary Fig S13).
When taken together these results suggest that tamoxifen
decreases LOX, LOX-L2 and fibronectin expression via HIF-
1α, and that the effect of tamoxifen on HIF-1α levels is
mechanically regulated by reducing myosin-2 dependent
HSCs contractility and tissue stiffness.
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Tamoxifen impairs directed migration via GPER
signalling
HSCs have been observed to migrate up a stiffness
gradient, a process also known as durotaxis and this
has been suggested to be a further step in the
perpetuation of fibrosis in the liver [29]. Since this pro-
cess was shown to be highly dependent on mechan-
otransduction, and our results here have shown
tamoxifen to inhibit mechanotransduction through
GPER, we investigated the ability of tamoxifen to inhibit
HSC durotaxis.
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We prepared PAA gels of dual rigidity to assess HSC
durotaxis in vitro following a protocol previously described
[29]. On these gels, control HSCs moved an average dis-
tance in the X-axis (up the stiffness gradient) of around 70
µm over 5 ½ h, with an average speed of 0.99 µm/min along
their individual paths. Ten- day tamoxifen treated cells and
tamoxifen combined with an ER antagonist treated cells
both showed no durotaxis, with significantly reduced cell
movement speeds of 0.20 µm/min and 0.15 µm/min,
respectively. When tamoxifen was combined with a GPER
antagonist, durotaxis was rescued (average distance in X-
axis= 61 µm over 5 ½ h) and cell speed became similar to
the control condition (0.98 µm/min) (Fig. 6 and videos 1–4).
Seventy-two-hour treatment of HSCs with tamoxifen or G1
also abrogated durotaxis behaviour, though GPER knock-
down was able to rescue the tamoxifen treated cells, with
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durotaxis comparable to the control condition (Supple-
mentary Figure S14 and videos 5–8). These combined
results show that tamoxifen inhibits the ability of HSCs to
migrate to stiffer substrates via GPER signalling.
Discussion
Estrogens regulate a manifold of physiological and patho-
logical processes and although endogenous estrogen is
mainly derived from the ovaries in premenopausal women
and mostly regarded as a female hormone [41], estrogen is
also produced in other tissues, such as adipose tissues and
arteries in both men and women [19, 42]. Until recently, the
field of estrogens was dominated by studies that explored
their transcriptional effects via nuclear estrogen receptors.
However, the last decade has witnessed an explosion of
interest in GPER-mediated estrogen signalling.
From our results, GPER comes to light as a compre-
hensive and effective mechanoregulator that targets the
activation of fundamental proteins in cell mechanics, such
as RhoA [22, 43] and MLC-2 to control force generation,
mechanosensing and durotaxis in hepatic stellate cells.
Increased levels of MLC-2 are required for the ability of
stromal cells to remodel the ECM [44] to perpetuate fibrosis
[45]. Likewise, high levels of active YAP, a mechan-
oresponsive transcriptional regulator [28], are indispensable
for the activation of tumour-associated myofibroblasts in the
stroma [46], and we show that YAP is downregulated in
tamoxifen treated HSCs. Due to the similarity of activated
HSCs to myofibroblasts, we posit that GPER is therefore
likely to influence the mechanical properties of other stro-
mal cells (Fig. 7).
The activation of HIF-1α is required for cell survival
under hypoxic conditions. The dense stroma that surrounds
solid tumours limits the accessibility of nutrients and
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Fig. 6 Tamoxifen treatment inhibits HSC durotaxis via GPER sig-
nalling. a Average cell movement distance on the soft-stiff rigidity
gradient compared to single rigidity soft and stiff substrates presented
as an average displacement (positive values indicate directed move-
ment towards stiff substrate, negative values towards soft substrate and
0 indicates random movement. n= 3 independent experiments. b Cell
movement speed on the soft-stiff rigidity gradient compared to single
rigidity soft and stiff substrates. c Representation of the average dis-
placements of HSCs. Quantification was done for 75 cells. Three
experimental replicates in all cases. Results are expressed as mean ±
sem. Anova and Tukey’s post hoc tests were used for the analysis
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oxygen to cells, promoting HIF-1α stabilisation [47]. The
rapid growth of cancer cells within HCC also leads to high
consumption of oxygen, further generating a hypoxic
environment [48]. Our data suggest that HIF-1α is the
unifying factor through which tamoxifen subsequently
reduces the levels of LOX, LOX-L2 and fibronectin in
HSCs. We suggest that HIF-1α may act as a converging
point to mechanically regulate the adaptive response of
HCC to hypoxia and the overall architecture of the tumour
microenvironment. We propose that this mechanical reg-
ulation of HIF-1α by tamoxifen in an oxygen-independent
manner may result in an effective reduction of cell fitness to
cope with hypoxic condition in HSCs, and potentially in
cancer cells as well, leading to decreasing fibrosis.
Development of fibrosis relies on positive feedback
pathways, including mechanotransduction and ECM protein
deposition [49] and durotaxis [29]. The directed migration
of cells to stiffer fibrotic areas leads to further activation by
mechanotransduction, leading to an increase in ECM pro-
tein production, which in turn, promotes a stiffer micro-
environment [13] that might lead to increased
chemoresistance in cancer cells [50]. Durotaxis can also
play a role in facilitating cross-talk between cancer cells and
activated stromal cells such as activated HSCs [51], and
therefore the inhibition of directed migration by tamoxifen,
combined with its ability to induce HSC quiescence, indi-
cates the multiple ways in which tamoxifen could
mechanically influence the tumor-stroma cross-talk.
Within the liver tissue, HSCs reside within the ECM, a
mixture of scaffolding proteins secreted by HSCs, among
other stromal cells. Interactions between cells are mostly
through paracrine signalling, as well as interactions with the
ECM proteins, rather than direct cell-cell interactions [9].
For our in vitro studies, we used culture-activated HSCs
seeded on fibronectin-coated glass, a widely employed
model, which recapitulates the activated phenotype in vivo
with good approximation [10]. However, the behaviour we
observe in vitro may well differ from that in vivo, where
HSCs are influenced by factors secreted by cancer cells and
other stromal cells, as well as the complex architecture of
the ECM [9], which are not present in our in vitro setup.
Further studies with HSCs are therefore necessary for a full
comprehension of the role of GPER in vivo.
Our work lays the foundations for further studies that
could directly influence therapeutic development. Tamox-
ifen is a widely used drug in clinics, with well-established
pharmacodynamics [52] and safety [53], and due to the
pleiotropic effects of estrogens and the commonality of
GPCR signaling pathways, it is possible that tamoxifen
regulates many genes involved in the function of
myofibroblast-like cells such as activated HSCs or cancer
associated fibroblasts. This could lead to development of
stromal reprogramming strategies in which GPER agonists
could modulate the fibrovascular stroma of HCC to increase
vascular density and perfusion by reducing overall solid
stress, achieved through inhibiting expression of collagen
and fibronectin. This would increase intratumoral drug
perfusion, while concurrently impeding the adaptive fitness
of tumour and stromal cells to survive under hypoxic con-
ditions (via HIF-1α) and thus promote widespread hypoxic
necrosis.
Materials and methods
Cell culture and antibodies
Primary, culture-activated human hepatic stellate cells
(HSCs), passage 3–6, (HHStec 5300; ScienCell, Carlsbad,
CA, USA) were cultured in phenol red medium (DMEM-
F12 HAM, cat. D6434, Sigma–Aldrich) supplemented with
10% foetal bovine serum (cat. 10500–064, Gibco), 1%
penicillin/streptomycin (P4333, Sigma–Aldrich, USA) and
1% Fungizone R amphotericin (15290–026, Gibco). These
cells were tested for mycoplasma contamination. Tamoxifen
(Z-4-hydroxytamoxifen, cat. H7904 Sigma–Aldrich, USA)
and 17 β-Estradiol (E2) (catalog number E8875, Sigma–
Aldrich, USA) were prepared in ethanol (stock solution
100 μM). The specific ER antagonist (ICI182780) [20],
GPER antagonist (G15) [21] and specifically designed
GPER agonist [23] were purchased from Tocris (cat. 1047,
3678 and 3577, respectively). ICI182780, G1 and G15 were
prepared in DMSO (stock solution 50 mM). To prevent any
estrogenic effects from phenol red, during the treatment
with tamoxifen, E2 or G1, HSCs were transferred to clear
medium with no phenol red (DMEM-F12 HAM, cat.
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Fig. 7 Model illustrating the mechanical effect of tamoxifen treatment
in HSCs. Tamoxifen activates GPER and this downregulates the
activity of RhoA, which in consequence decreases the levels of
pMLC-2 (active form). The decrease in MLC-2 activation leads to
suppressing mechanosensing, force generation and HSCs ability to
mechanically regulate the synthesis of ECM proteins and HIF-1alpha
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D8437, Sigma–Aldrich, USA) supplemented with 10%
double charcoal stripped foetal calf serum—DCSS (cat. 02-
46-850, First Link, Wolverhampton, UK), 1% penicillin/
streptomycin (P4333, Sigma Aldrich, USA) and 1% Fun-
gizone R Amphotericin (15290-026, Gibco, USA). For
subsequent experiments media (without phenol red) and
DCSS were used. In all experiments tamoxifen was used
at 5 µM and E2 at 0.1 µM. GPER agonist G1 was used at
1 µM. ER and GPER antagonists (ICI182780 and G15)
were added simultaneously with tamoxifen in all experi-
ments; the concentration used for both was 1 µM. This
range of concentrations have been used effectively in pre-
vious studies [54]. Tamoxifen treatment was done for 72 h
or 10 days. E2 and G1 treatments were conducted for 72 h.
Media was replenished every 72 h in all cases. For GPER
and HIF-1α knockdowns, siRNA for GPER (Santa Cruz
Biotechnology, cat. sc-60743) and siRNA for HIF-1A (cat.
Sc-35561, from Santa Cruz Biotechnology USA), respec-
tively, were used to transfect HSCs before the specific
treatment. Human plasma fibronectin (FC010) was from
Millipore USA. The followings are antibodies: MLC-2
(Millipore USA, MABT180, 1/200), pMLC-2 /Thr18/Ser19
(Cell Signaling USA, 3674, 1/200), total RhoA (Millipore
USA, 04–822 USA, WB 1/1000), pRhoA (Abcam UK,
ab41435, WB 1/100), YAP (Santa Cruz Biotechnology
USA, sc-101199, 1/100), collagen-I (Abcam UK, ab34710,
1/100), fibronectin (Abcam UK ab2413, 1/500), HIF-1
alpha (Abcam UK, ab2185 1/200), LOX (Santa Cruz Bio-
technology USA, sc-373950, 1/100), LOX-L2 (Santa Cruz
Biotechnology USA, sc-66950, 1/50), αSMA (Abcam UK,
ab7817, 1/200), Vimentin (DAKO UK, M0725, 1/100),
GPER (Abcam UK, ab39742, 1/1000 and 1/2500), GPER
(Abcam UK, ab154069, 1/1000), anti-Mouse HRP (Invi-
trogen USA, 626580, 1/2,000), anti-Rabbit HRP (Abcam
UK, ab137914, 1/200) and a-Mouse 488 (Invitrogen USA,
A11029, 1/400). The GPER plasmid used to overexpress
GPER was obtained from Sino Biological, UK (catalog
number HG11264-ACG), and a stop codon was inserted
between the GPER and GFP sequences by site directed
mutagenesis. pEGFP-MRLC1 (constitutively active MLC-
2) was a gift from Tom Egelhoff, Addgene USA plasmid
#35680.
Immunofluorescence staining
Cell immunofluorescence staining was done on coverslips
coated with 10 μg ml−1 fibronectin (Gibco, phe0023). Fol-
lowing pertinent treatment cells were fixed with 4% paraf-
ormaldehyde (Sigma, P6148) in D-PBS (Sigma, D8537) for
10 min, and then blocked and permeabilized with 0.2%
BSA–0.1%Triton (Sigma, T8787) in PBS for 30 min. After
blocking, cells were incubated with primary antibodies
prepared in blocking solution for 1 h at room temperature in
a humidified chamber. Then, cells were washed in D-PBS
and incubated with Alexa Fluor 488-conjugated secondary
antibodies and Phalloidin (Invitrogen, A22283, 1/1,000
dilution) prepared in PBS for 30 min at room temperature.
Finally, coverslips were washed in PBS and mounted in
mounting reagent with 4,6-diamidino-2-phenylindole
(Invitrogen, P36931). Immunofluorescent images were
taken with Nikon Ti-e inverted microscope (Nikon, King-
ston-upon-Thames, United Kingdom) with NIS elements
software.
RT–PCR
Total RNA was extracted using the RNeasy Mini kit (Qiagen,
74104) and 1 μg of total RNA was reverse-transcribed using
the High-Capacity RNA-to-cDNA kit (Applied Biosystems,
4387406) according to the manufacturer’s instructions. qPCR
was performed using the SYBR Green PCR Master Mix
(Applied Biosystems, 4309155) with 100 ng cDNA input in
20 μl reaction volume. RPLP0 expression level was used for
normalization as a housekeeping gene. The primer sequences
were as follow: RPLP0: forward 5′-CGGTTTCTG
ATTGGCTAC-3′, and reverse 5′-ACGATGTCACTTC
CACG-3′; CTGF: forward 5′-TTAAGAAGGGCAAAAAG
TGC-3′, and reverse 5′-CATACTCCACAGAATTTA
GCTC-3′; ANKDR1: forward 5′-TGAGTATAAACGGA
CAGCTC-3′, and reverse 5′-TATCACGGAATTCGATCTG
G-3′; a-SMA: forward 5′CATCATGAAGTGTGACATCG
-3′, and reverse 5′GATCTTGATCTTCATGGTGC-3′;
Collagen-I: forward 5′-GCTATGATGAGAAATCAACCG-
3′, and reverse 5′-TCATCTCCATTCTTTCCAGG-3′; fibro-
nectin: forward 5′-CCATAGCTGAGAAGTGTTTTG-3′,
and reverse 5′-CAAGTACAATCTACCATCATCC-3′; HIF-
1A: forward 5′-AAAATCTCATCCAAGAAGCC-3′, and
reverse 5′-AATGTTCCAATTCCTACTGC-3′; LOX: for-
ward 5′-CAACATTACCACAGTATGGATG-3′, and reverse
5′-TAGTCACAGGATGTGTCTTC-3′; LOX-L2; forward
5′-GATGTACAACTGCCACATAG-3′, and reverse 5′-
GACAGCTGGTTGTTTAAGAG-3′. All primers were used
at 300 nM final concentration. The relative gene expression
was analysed by comparative 2−ΔΔct method.
The procedures for the analysis of gene expression using
TCGA data, traction forces using elastic pillars, cell
mechanosensing, durotaxis, atomic force microscopy,
GLISA and the statistical analysis can be found in supple-
mentary methods.
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